The ocular surface was found to change in patients treated with prostaglandin analogues, according to a literature review published in the Journal of Ophthalmology.
“We focused on the effect on the cornea and conjunctiva of [prostaglandin analogue]-treated individuals, with the following aspects summarized: corneal biomechanical properties, [central corneal thickness], conjunctiva, wound healing and dry eye,” Wencui Shen, MD, of the Tianjin Eye Hospital and Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science at Nankai University in Tianjin, China, and colleagues wrote.
The main issues found with PGA therapies are the side effect of conjunctival hyperemia and the delay found in corneal wound healing, the researchers stated. Furthermore, studies have also demonstrated that a large proportion of patients using topical PGAs suffer from ocular surface disease (OSD), with half suffering from dry eye.
This review shows there is a significant relationship between changes in ocular surface and PGAs. PGAs demonstrate a considerable influence on ocular surface of patients, whether in direct structure of the cornea or in the pathological change of OSD, they said.
“These disadvantages of PGAs encourage us to invent more precise methods recording medicated IOP and to develop more effective and safer antiglaucoma drugs,” the authors wrote.
The researchers advised that IOP measurements should be adjusted during therapy, and that OSD caused by PGAs should be recognized at patient follow-up. – by Erin T. Welsh
Disclosure: The authors report no relevant financial disclosures.